New ADLM Leadership Signals a Strategic Pivot Toward AI and Health Equity

WASHINGTON, DC – June 30, 2026 – The Association for Diagnostics & Laboratory Medicine (ADLM) has announced a new slate of leaders, a move that signals more than a simple changing of the guard. The election of Dr. Christina (Tina) Lockwood as president-elect is a clear indicator of the organization's strategic direction, pointing toward a future where laboratory medicine is central to solving healthcare's most complex challenges: technological disruption, health equity, and access to care.

Dr. Lockwood, a distinguished professor and director at the University of Washington School of Medicine, will begin her term as president-elect in August 2026 before ascending to the presidency in 2027. Her appointment, alongside a newly elected board, comes at a pivotal moment. The field of diagnostics is no longer confined to the sterile environment of the lab; it is at the forefront of a data-driven, hyper-personalized healthcare revolution. The new leadership's collective expertise suggests ADLM is positioning itself not just to react to this evolution, but to actively shape it.

A Vision for the Next Frontier

In her first public statement following the election, Dr. Lockwood articulated a vision that extends far beyond incremental technical updates. "Laboratory medicine is evolving rapidly, and the pace of change makes ADLM's work more important than ever," she stated. "At the same time, we must address important challenges, including improving access to testing, advancing health equity, and ensuring the responsible use of emerging tools in data science and artificial intelligence."

This statement is a mission brief for the modern era of healthcare. Dr. Lockwood’s own career provides a blueprint for this mission. As a leader in molecular and genomic diagnostics at the University of Washington, her work has focused on translating complex science—like cell-free DNA diagnostics for oncology and prenatal screening—into practical tools that directly improve patient care. Her expertise is not in technology for technology's sake, but in its tangible application.

Her extensive service across national regulatory and quality assurance bodies, from the NIH to The Joint Commission, demonstrates a deep understanding of the complex ecosystem in which these new technologies must operate. This background is critical. The successful integration of AI and genomics into mainstream medicine depends less on the brilliance of the algorithm and more on navigating the labyrinth of regulation, reimbursement, and clinical workflow integration. Dr. Lockwood’s experience suggests she is uniquely prepared to lead ADLM through this intricate landscape.

Decoding the New Diagnostic Era

Dr. Lockwood's focus on AI, equity, and access is not arbitrary; it reflects the three seismic shifts redefining the value and function of laboratory medicine. The challenge of "ensuring the responsible use" of AI is paramount. As machine learning models become more adept at interpreting everything from pathology slides to complex genomic data, the industry faces critical questions about algorithmic bias, data privacy, and the validation of black-box systems. Responsible use means creating frameworks that allow AI to augment human expertise without inheriting or amplifying human biases, a task that requires both technical acumen and ethical foresight.

Similarly, the push for health equity is transforming the mandate of diagnostics. For decades, the most advanced tests were often the least accessible, available only at major academic centers and to patients with the best insurance. This dynamic risks creating a two-tiered system of care, where breakthroughs like personalized cancer treatment widen, rather than close, health disparities. ADLM's focus on improving access—likely through advocacy for point-of-care testing, more affordable diagnostics, and equitable reimbursement policies—is a direct effort to counter this trend and ensure that innovation serves everyone.

This mission is particularly relevant in the context of genomic medicine and liquid biopsies, fields where Dr. Lockwood is an expert. These technologies hold the promise of early disease detection and highly personalized treatment, but their high cost and complexity present significant barriers. By placing a leader with this expertise at the helm, ADLM is signaling its commitment to making the promise of personalized medicine a reality for a broader population.

A Collective of Diverse Expertise

Dr. Lockwood is not embarking on this mission alone. The new leadership team reflects a deliberate strategy of assembling diverse expertise from across the healthcare spectrum. The election of M. Laura Parnas, a senior director at diagnostics giant Sysmex America, as ADLM secretary brings a crucial industry perspective to the board. Her experience navigating the commercial and regulatory aspects of bringing new diagnostic technologies to market will be invaluable.

New board members Danyel H. Tacker, a professor at West Virginia University with a focus on IT and technology standardization, and Alison Woodworth, a clinical director for global laboratory services at CTI Clinical Trials & Consulting, add further depth. This blend of academic rigor, clinical trial experience, and IT systems knowledge creates a leadership body that understands the full lifecycle of a diagnostic tool, from initial discovery and regulatory approval to clinical implementation and large-scale data management.

This strategic assembly of talent extends to the new nominating committee and the inclusion of leaders from ADLM's specialized councils. The message is clear: solving the complex problems of modern healthcare requires a multi-disciplinary, collaborative approach. The era of siloed expertise is over. The new leadership at the Association for Diagnostics & Laboratory Medicine is not just a roster of impressive names; it is a carefully constructed team built to guide a 70,000-member global organization through a period of unprecedented change and opportunity.